The prime minister\u2019s business adviser, Varun Chandra, flew to Washington this week to discuss tariffs.<\/p>\n
In parallel, the U.K. government is locked in talks with companies over NHS drug pricing, with Science Minister Patrick Vallance recently hinting the NHS will need to pay more if Britain wants to stay attractive for investment.<\/p>\n
However, Kyle indicated he thinks the sector\u2019s concerns have been overstated, saying: \u201cThe pharma companies are very good negotiators. They are hard negotiators, and they know how to use the media and the press to do it.\u201d<\/p>\n
\u201cBut we are tough negotiators too, and we are in the process of negotiating lots of different arrangements and agreements and investments into pharma.\u201d<\/p>\n
Kyle insisted the U.K. continues to \u201chave one of the best life sciences communities in the world,\u201d pointing to a recent \u00a31 billion investment by German medicines giant BioNTech. The government is continuing to look for ways to make it easier to roll out innovative medicines across the U.K.\u2019s health system, he said.<\/p>\n
Steel talks continue<\/p>\n
Elsewhere, Kyle said London is \u201cnot giving up on on moving forward in a whole range of areas,\u201d related to the U.K.\u2019s trade pact with the U.S.<\/p>\n","protected":false},"excerpt":{"rendered":"The prime minister\u2019s business adviser, Varun Chandra, flew to Washington this week to discuss tariffs. In parallel, the…\n","protected":false},"author":2,"featured_media":463568,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,4],"tags":[74019,748,12849,393,4884,1144,60394,10057,712,1218,479,16,15,49,1764],"class_list":{"0":"post-463567","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-uk","8":"category-united-kingdom","9":"tag-biotech-drugs","10":"tag-britain","11":"tag-drug-pricing","12":"tag-england","13":"tag-great-britain","14":"tag-northern-ireland","15":"tag-peter-kyle","16":"tag-pharma","17":"tag-scotland","18":"tag-steel","19":"tag-tariffs","20":"tag-uk","21":"tag-united-kingdom","22":"tag-united-states","23":"tag-wales"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115294313229135777","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/463567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=463567"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/463567\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/463568"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=463567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=463567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=463567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}